Thermo Fisher's Q1: Robust Growth & Strong Guidance

Thermo Fisher Scientifics Q1 report shows a six percent revenue increase to $11 billion, with adjusted operating income and earnings per share matching that growth. Theyre raising full-year guidance, signaling six to eight percent overall growth. The company closed the Clario acquisition for $9 billion, adding to Q1 revenue and boosting clinical research capabilities. Pharma and biotech markets grew mid-single digits, while academic and government slipped low single digits. Customers and execs are feeling the momentum, with strong share gains and upbeat vibes from biotech funding rebounds. New launches and collaborations are firing up labs, and the company generated $830 million in free cash flow, repurchased $3 billion in shares, and hiked dividends ten percent. Organic growth is pegged at three to four percent, with Clario integration and innovation driving steady gains. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/818f254e6c1f9244